ClinicalTrials.gg
RecruitingNCT05683067MICROFONUpdated Jul 20, 2023

Microcirculation and Vascular Function After Fontan Surgery

An observational study in Congenital Heart Disease, sponsored by University of Leicester. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by University of Leicester · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
16 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Heart Defects, Congenital with a site in United Kingdom — 10 open to participants now, 11 under way, none of them phase 3. Heart Defects, Congenital · United Kingdom.

Planned enrollment
10th of 14
75 · median 300
Started
2023
with 1 other
Observational
14 of 32
6 open now
Primary completion
2024-10
later than 2 of 10 live
Registered
23rd of 32
by date
Lead sponsor
2 of 32
University of Leicester

Among the 32 studies in Heart Defects, Congenital with a site in United Kingdom, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2023, is one of 14 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 23rd registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

10 of the 32 studies in Heart Defects, Congenital with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 16 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Heart Defects, Congenital with a site in United Kingdom, or all of them as a file.
02

Study summary

Fontan Surgery is done for children with only one working lower chamber of the heart called the 'Single Ventricle'. This surgery involves making connections between the two big veins that drain oxygen deficient blood to the heart and the lung artery directly. Fontan patients may develop long-term complications such as reduced heart function or oxygen levels, increased pressure in the veins, liver or kidney problems etc. The reasons for these complications are poorly understood. The small blood vessels in the body or 'microcirculation' are tiny (can be seen only by microscope) and they supply food and oxygen to the tissues. Very little is known about what happens to the microcirculation in adult Fontan survivors . In this study the investigator want to understand why these adult Fontan survivors develop complications by looking at their microcirculation and comparing them with healthy people and those who were operated for other congenital heart diseases. The study will be conducted in East Midlands Congenital Heart Centre, Glenfield Hospital.

Leicester.

Read the detailed description

In normal heart, there are two working lower chambers where one chamber pumps the blood to the lungs and other chamber pumps the blood to the body. However, some congenital heart conditions have only one working lower chamber of the heart called the 'Single Ventricle'. This condition is often associated with hole between the heart chambers with increased or decreased blood flow to the lungs. This can lead to mixing of blood in the heart with low oxygen levels in the body. The surgery for single ventricle is usually performed in stages starting from the infancy. Fontan surgery is the last stage where the two big veins that return the blood to the heart is connected to the lung artery directly. This surgery improves the oxygen levels in the blood and lessens the burden on the single ventricle. The blood is not pumped to the lungs by the heart but rather enters passively to the lungs through this new surgical connection. Some people operated for Fontan surgery have many short-term and long-term complications such as increased pressure in veins , poor heart function and low oxygen levels in the blood. In particular, the organs below the chest such as kidney, liver and gut are affected, and all of these predict poor outcomes. The reason for these complications are poorly understood.

The small blood vessels in the body or 'microcirculation' are very tiny and are less than 150 microns in diameter. These includes arterioles, capillaries, and venules. Very little is known about the microcirculation in adult Fontan survivors and its association with aortic stiffness, late complications, and quality of life. In this study, The investigators want to look at the blood vessels in adult Fontan survivors, people operated for other congenital heart diseases, and healthy volunteers using a special microscope called Hand Held Capillary Microscopy. The investigators will visualize their blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain. The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional. The investigator will also collect the information about the quality of life using questionnaires as few studies have shown that the quality of life is affected in adult Fontan survivors and it was associated with poor vascular function. Age matched healthy controls and adults survivors of other congenital heart surgeries will also undergo these tests for comparison purpose. This study will be conducted at East Midlands Congenital Heart Centre, Glenfield Hospital, Leicester.

03

Conditions studied

  • Congenital Heart Disease

Keywords

  • Microcirculation
  • Fontan Procedure
  • Vascular Function
04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

In this study, The investigator want to look at the blood vessels and test the vascular function in Fontan survivors, people operated for other congenital heart diseases, and healthy volunteers between 16 and 50 years of age

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients operated for Fontan procedure or other congenital heart conditions
  • Patients ≥ 16 - 50 years of age
  • Participant/Parents/Guardian or legal representative willing and able to give for participation in the study
  • Able (in the Investigators opinion) and willing to comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • Low blood pressure (90/60 mmHg with symptoms or on intravenous inotropes for maintenance of blood pressure)
  • Raynaud's disease
  • diseases
  • Down's syndrome as they have lower risk for vascular anomalies compared with the general population and may have different microvasculature
  • Treatment with sympathomimetic drugs
  • Atrial fibrillation or any other arrhythmia which might interfere with vascular function assessments.
  • Documented peripheral vascular disease
  • Skin disorders such as psoriasis or significant eczema
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Tremor or Inability to keep the hand still for 20 minutes.

Note: Patients treated with angiotensin converting enzyme inhibitors or angiotensin receptor inhibitors, beta blockers, vasodilators, diuretics and digoxin will be included in the study as the majority of Fontan survivors are taking one or more of these drugs for optimization of their circulation or for symptom management. Patients treated with anticoagulants and antiplatelets will be included in the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fontan Survivors

    The investigator will include Fontan survivors between 16-50 years of age for the study.

    Other: Hand Held Capillary Microscopy · Other: Mobile 'O' Graph · Other: quality of life using questionnaires

  • People operated for congenital heart diseases

    The investigator will include people operated for other types of congenital heart diseases such as tetralogy of Fallot, transposition of great arteries between 16 and 50 years of age

    Other: Hand Held Capillary Microscopy · Other: Mobile 'O' Graph · Other: quality of life using questionnaires

  • Healthy volunteers

    The investigator will include healthy volunteers between 16 to 50 years of age for comparison purpose.

    Other: Hand Held Capillary Microscopy · Other: Mobile 'O' Graph · Other: quality of life using questionnaires

Interventions

  • OtherHand Held Capillary Microscopy

    The investigator will visualize the blood vessel appearance, number, and size they have in their hands, feet, and under the tongue. This procedure is non-invasive and will not cause any pain.

  • OtherMobile 'O' Graph

    The aortic stiffness will be measured non-invasively using a special blood pressure monitor called Mobile 'O' Graph, which is about size of a pocket diary. 24 hour blood pressure monitoring is optional.

  • Otherquality of life using questionnaires

    The investigator will evaluate the quality of life using questionnaires such as EQ-5D-5L questionnaire and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)

06

What researchers measure

Primary outcomes

  1. In this study, the investigator want to look at the microcirculation using hand held capillary microscopy in the young and adult Fontan survivors compared to the age matched healthy people and the people operated for other congenital heart surgeries.

    The microcirculation will be studied in the skin of the hands, feet, and the mouth using handheld capillary microscopy

    Time frame: One year

Secondary outcomes

  1. The investigator want to measure the central blood pressure in the young and adult Fontan survivors compared to the age matched healthy people and the people operated for other congenital heart surgeries.

    The central blood pressure, pulse wave velocity, and the augmentation index will be assessed by Mobile O Graph blood pressure monitor

    Time frame: One year

  2. The investigator will measure the functional outcomes in young and adult Fontan survivors using questionnaires and study its relationship with microvascular assessments and vascular function.

    The functional status will be assessed by Minnesota living with heart failure questionnaire

    Time frame: One Year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — This will be decided soon by the study team

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Oct 2024, 16 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 16 months is below that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Jan 12, 2023
StartActual
May 12, 2023
Primary completionEst.
Oct 1, 2024
CompletionEst.
Oct 1, 2024
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05683067
Responsible party
Sponsor
First posted
Jan 12, 2023
Start date
May 12, 2023
Primary completion
Oct 1, 2024 (estimated)
Completion
Oct 1, 2024 (estimated)
Last update
Jul 20, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion